PUBLISHER: The Business Research Company | PRODUCT CODE: 1217169
PUBLISHER: The Business Research Company | PRODUCT CODE: 1217169
Contact us about how to customize the report with add-on data.
“Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on isothermal nucleic acid amplification technology (inaat) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for isothermal nucleic acid amplification technology (inaat) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The isothermal nucleic acid amplification technology (inaat) market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Companies Mentioned: Alere; Biomeriux; Qiagen; Becton; Dickinson & Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Major players in the market are: Alere, Biomeriux, Qiagen, Becton, Dickinson & Company, Hologica, Lucigen, Quidel Corporation, New England Biolabs, Nugen, Ustar Biotechnologies, Thermo Fisher Scientific, BioHelix, Meridian Bioscience, New England Biolabs Inc., Novartis Diagnostics, Sharp Corp, Sony Corp, Panasonic, Toshiba Corp, Rohm, PhilipsHologic-Gen-Probe, BetaLED, Avago technologies, and Grifols.
The global isothermal nucleic acid amplification technology (inaat) market will grow from $3.2 billion in 2022 to $3.53 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The isothermal nucleic acid amplification technology (inaat) market is expected to grow to $5.47 billion in 2027 at a CAGR of 11.6%.
The isothermal nucleic acid amplification technology (INAAT) market includes revenue earned by reaction systems and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
Isothermal nucleic acid amplification technology (INAAT) is technique that amplified DNA samples. Isothermal nucleic acid amplification technologies are used to amplify DNA sequence from two different nucleic acids segments at the constant temperature.
North America was the largest region in the isothermal nucleic acid amplification technology (INAAT) market market in 2022. Western Europe was the second largest region in the isothermal nucleic acid amplification technology (INAAT) market. The regions covered in the isothermal nucleic acid amplification technology (INAAT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main product types of isothermal nucleic acid amplification technology are instrument and reagent. A reagent is a material or compound that is added to a system to produce a chemical reaction or to determine whether or not a reaction occurred. The various technology used are NASBA, and HAD that are applied for blood screening, infectious disease diagnostics, and cancer. The various end users include hospital, reference laboratories, and others.
The incidence of infectious diseases such as H. influenzae, S. pneumonia (respiratory tract infections), N. gonorrhoeae, C. trachomatis (genital infections), and TB are increasing and require isothermal nucleic acid amplification technology (INAAT) to diagnose them. For instance, according to World Health Organization 17 million people lose their lives to infectious diseases every year. Another report by Centres for Disease Control show that number of diseases from mosquitoes, ticks and fleas like West Nile, Zika, Malaria and Lyme disease increased three times. Similarly, as per a survey done by NCBI, around 50% of the population in the United States (approx. 157 million) was suffering from at least one chronic disease in 2020. Increase in infectious or chronic disease drives the demand for diagnosing through isothermal nucleic acid amplification technology.
The market for isothermal nucleic acid amplification technology is strictly regulated by stringent regulatory policies that govern the functioning, approvals and standards set for the manufacturers of this market. These regulations discourage companies to invest in new products for research and development or enter new markets. For example, the administration of US food and drugs (USFDA) requires multi-laboratory validation of a loop-mediating isothermal amplification which takes twice as much time as the Commission for European regulatory to review the process. Long regulatory procedures delay the scope for further study of the safety and efficacy of devices and affects the operating cycle of the vendors thereby adversely affecting the growth of the market.
Nanostructures are being incorporated to in vitro diagnostics and in vitro rapid diagnostic tests (RDT) in order to improve existing tests and make them more effective or create innovative diagnostic test approaches that are incorporated in point-of-care applications. Nanostructures/nanotechnology uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. For instance, a range of RDTs have been developed to diagnose syphilis such as AccuBioTech (Accu-Tell Rapid Syphilis Test), Alere, Inc. (Alere Determine), Alere/Standard Diagnostics (SD Syphilis 3.0), The Tulip Group/Qualpro (Syphicheck - WB), Cypress Diagnostics (Syphilis Rapid Test), and Omega Diagnostics (Visitect Syphilis). These RDTs allow patients to be diagnosed at the point-of-care (POC).
The isothermal nucleic acid amplification technology market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. For instance, according to USFDA, each medical device is classified into three groups which is class 1, class 2 & class 3. Class 1 devices require less regulatory control and class 3 requires the most. However, devices which are not been marketed before as in the case of INAAT devices, will fall under class 3 devices as per the medical device amendment. Such devices require approval of a Pre-Market Application (PMA) under the federal law. Premarket approval (PMA) is the scientific and regulatory review process of the FDA to assess the safety and efficacy of medical devices of Class 3.
In July 2021, Sapphiros, a KKR-backed platform focused on developing the next generation of diagnostic technologies acquired Biocrucible Ltd for an undisclosed amount. With this acquisition, Sapphiros aimed to develop market-leading consumer molecular diagnostics. Biocrucible Ltd, a biotechnology company based in the UK, is a pioneer in the acceleration and augmentation of biochemical kinetics through the use of their Molten TagsTM technology.
The countries covered in the market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).
The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.
The isothermal nucleic acid amplification technology (INAAT) market research report is one of a series of new reports from The Business Research Company that provides isothermal nucleic acid amplification technology (INAAT) market statistics, including isothermal nucleic acid amplification technology (INAAT) industry global market size, regional shares, competitors with a isothermal nucleic acid amplification technology (INAAT) market share, detailed isothermal nucleic acid amplification technology (INAAT) market segments, market trends and opportunities, and any further data you may need to thrive in the isothermal nucleic acid amplification technology (INAAT) industry. This isothermal nucleic acid amplification technology (INAAT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.